Expression Patterns and Prognostic Value of MA-related Genes in Colorectal Cancer

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2019 Aug 10

PMID 31396313

Citations 102

Authors

Xin Liu

Liwen Liu

Zihui Dong

Jianhao Li

Yan Yu

Xiaolong Chen

Fang Ren

Guangying Cui

Ranran Sun

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC), including colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ), is one of the most prevalent malignancies worldwide. N-methyladenosine (mA) is a ubiquitous RNA modification that plays a vital role in human tumors, but its expression patterns and prognostic value in CRC have not yet been determined. Here, we first used the Cancer Genome Atlas (TCGA), the Gene Expression Omnibus (GEO) and the Human Protein Atlas (HPA) databases and a tissue microarray (TMA) cohort to verify the expression of mA-related genes at the mRNA and protein levels. We found that most mA-related genes were substantially upregulated in tumor tissues compared with normal tissues, but METTL14, YTHDF3 and ALKBH5 were downregulated in CRC. There was no obvious difference in FTO. In addition, WTAP, METTL16, HNRNPC and YTHDC1 were abundantly expressed in COAD but not in READ. Moreover, immunofluorescence (IF) analyses of SW480 and HCT116 cells showed that most of the mA-related proteins were expressed in the nucleus and cytoplasm. Survival analysis demonstrated that the expression levels of METTL3, METTL14, METTL16, FTO and ALKBH5 were associated with the clinical outcomes of CRC patients. Taken together, all the results revealed that mA-related genes were dysregulated in CRC and might play a significant role in the progression of CRC.

Citing Articles

WTAP-Mediated N6-Methyladenosine Modification Promotes Gastric Cancer Progression by Regulating MAP2K6 Expression.

Han S, Jiang H, Wang J, Li C, Liu T, Xuan M J Cancer. 2025; 16(5):1420-1437.

PMID: 39991580 PMC: 11843227. DOI: 10.7150/jca.98559.

High WTAP expression level as a promising biomarker for poor prognosis in colorectal cancer: a pilot study.

Relucenti M, Tito C, Mercantini P, Pilozzi E, Barbaranelli C, Cristiano L Eur J Histochem. 2024; 68(4).

PMID: 39679554 PMC: 11696005. DOI: 10.4081/ejh.2024.4145.

Role of the mA demethylase ALKBH5 in gastrointestinal tract cancer (Review).

Zhang L, Jing M, Song Q, Ouyang Y, Pang Y, Ye X Int J Mol Med. 2024; 55(2).

PMID: 39611478 PMC: 11637504. DOI: 10.3892/ijmm.2024.5463.

Modulation of host N6-methyladenosine modification by gut microbiota in colorectal cancer.

Jiang T, Wang H, Cheng W, Xie C World J Gastroenterol. 2024; 30(38):4175-4193.

PMID: 39493326 PMC: 11525875. DOI: 10.3748/wjg.v30.i38.4175.

METTL14-mediated m6A mRNA modification of G6PD promotes lung adenocarcinoma.

Wu W, Li M, Wu Y, Wei Q, Yu N Cell Death Discov. 2024; 10(1):361.

PMID: 39138186 PMC: 11322390. DOI: 10.1038/s41420-024-02133-w.

References

Compton C . Colorectal carcinoma: diagnostic, prognostic, and molecular features. Mod Pathol. 2003; 16(4):376-88. DOI: 10.1097/01.MP.0000062859.46942.93. View

Wang X, Lu Z, Gomez A, Hon G, Yue Y, Han D . N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2013; 505(7481):117-20. PMC: 3877715. DOI: 10.1038/nature12730. View

Meyer K, Jaffrey S . The dynamic epitranscriptome: N6-methyladenosine and gene expression control. Nat Rev Mol Cell Biol. 2014; 15(5):313-26. PMC: 4393108. DOI: 10.1038/nrm3785. View

Gilbert W, Bell T, Schaening C . Messenger RNA modifications: Form, distribution, and function. Science. 2016; 352(6292):1408-12. PMC: 5094196. DOI: 10.1126/science.aad8711. View

Ma J, Yang F, Zhou C, Liu F, Yuan J, Wang F . METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N -methyladenosine-dependent primary MicroRNA processing. Hepatology. 2016; 65(2):529-543. DOI: 10.1002/hep.28885. View

Kwok C, Marshall A, Rasko J, Wong J . Genetic alterations of mA regulators predict poorer survival in acute myeloid leukemia. J Hematol Oncol. 2017; 10(1):39. PMC: 5290707. DOI: 10.1186/s13045-017-0410-6. View

Cui Q, Shi H, Ye P, Li L, Qu Q, Sun G . mA RNA Methylation Regulates the Self-Renewal and Tumorigenesis of Glioblastoma Stem Cells. Cell Rep. 2017; 18(11):2622-2634. PMC: 5479356. DOI: 10.1016/j.celrep.2017.02.059. View

Roignant J, Soller M . mA in mRNA: An Ancient Mechanism for Fine-Tuning Gene Expression. Trends Genet. 2017; 33(6):380-390. DOI: 10.1016/j.tig.2017.04.003. View

Roundtree I, Evans M, Pan T, He C . Dynamic RNA Modifications in Gene Expression Regulation. Cell. 2017; 169(7):1187-1200. PMC: 5657247. DOI: 10.1016/j.cell.2017.05.045. View

10.

Bohnsack M, Sloan K . The mitochondrial epitranscriptome: the roles of RNA modifications in mitochondrial translation and human disease. Cell Mol Life Sci. 2017; 75(2):241-260. PMC: 5756263. DOI: 10.1007/s00018-017-2598-6. View

11.

Zhou Y, Hambly B, McLachlan C . FTO associations with obesity and telomere length. J Biomed Sci. 2017; 24(1):65. PMC: 5580219. DOI: 10.1186/s12929-017-0372-6. View

12.

Chen M, Wei L, Law C, Tsang F, Shen J, Cheng C . RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2017; 67(6):2254-2270. DOI: 10.1002/hep.29683. View

13.

Cai X, Wang X, Cao C, Gao Y, Zhang S, Yang Z . HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g. Cancer Lett. 2017; 415:11-19. DOI: 10.1016/j.canlet.2017.11.018. View

14.

Zhou S, Bai Z, Xia D, Zhao Z, Zhao R, Wang Y . FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting β-catenin through mRNA demethylation. Mol Carcinog. 2018; 57(5):590-597. DOI: 10.1002/mc.22782. View

15.

Taketo K, Konno M, Asai A, Koseki J, Toratani M, Satoh T . The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018; 52(2):621-629. DOI: 10.3892/ijo.2017.4219. View

16.

Ding C, Zou Q, Ding J, Ling M, Wang W, Li H . Increased N6-methyladenosine causes infertility is associated with FTO expression. J Cell Physiol. 2018; 233(9):7055-7066. DOI: 10.1002/jcp.26507. View

17.

Zhao X, Chen Y, Mao Q, Jiang X, Jiang W, Chen J . Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Biomark. 2018; 21(4):859-868. DOI: 10.3233/CBM-170791. View

18.

Tang J, Wang F, Cheng G, Si S, Sun X, Han J . Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability. J Exp Clin Cancer Res. 2018; 37(1):40. PMC: 5827993. DOI: 10.1186/s13046-018-0706-6. View

19.

Nishizawa Y, Konno M, Asai A, Koseki J, Kawamoto K, Miyoshi N . Oncogene c-Myc promotes epitranscriptome mA reader YTHDF1 expression in colorectal cancer. Oncotarget. 2018; 9(7):7476-7486. PMC: 5800917. DOI: 10.18632/oncotarget.23554. View

20.

Pan Y, Ma P, Liu Y, Li W, Shu Y . Multiple functions of mA RNA methylation in cancer. J Hematol Oncol. 2018; 11(1):48. PMC: 5870302. DOI: 10.1186/s13045-018-0590-8. View